Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial.
Ripoll C, Platzer S, Franken P, Aschenbach R, Wienke A, Schuhmacher U, Teichgräber U, Stallmach A, Steighardt J, Zipprich A; Liver-HERO Study Group. Ripoll C, et al. Trials. 2023 Apr 5;24(1):258. doi: 10.1186/s13063-023-07261-9. Trials. 2023. PMID: 37020315 Free PMC article. Clinical Trial.
Compromised function of natural killer cells in acute and chronic viral hepatitis.
Lunemann S, Malone DF, Hengst J, Port K, Grabowski J, Deterding K, Markova A, Bremer B, Schlaphoff V, Cornberg M, Manns MP, Sandberg JK, Ljunggren HG, Björkström NK, Wedemeyer H. Lunemann S, et al. Among authors: port k. J Infect Dis. 2014 May 1;209(9):1362-73. doi: 10.1093/infdis/jit561. Epub 2013 Oct 23. J Infect Dis. 2014. PMID: 24154737
Effects of HDV infection and pegylated interferon α treatment on the natural killer cell compartment in chronically infected individuals.
Lunemann S, Malone DF, Grabowski J, Port K, Béziat V, Bremer B, Malmberg KJ, Manns MP, Sandberg JK, Cornberg M, Ljunggren HG, Wedemeyer H, Björkström NK. Lunemann S, et al. Among authors: port k. Gut. 2015 Mar;64(3):469-82. doi: 10.1136/gutjnl-2014-306767. Epub 2014 Apr 10. Gut. 2015. PMID: 24721903 Clinical Trial.
Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease.
Maasoumy B, Port K, Deterding K, Höner Zu Siederdissen C, Markova AA, Rogalska-Taranta M, Manns MP, Wedemeyer H, Cornberg M. Maasoumy B, et al. Among authors: port k. Eur J Gastroenterol Hepatol. 2014 Aug;26(8):836-45. doi: 10.1097/MEG.0000000000000121. Eur J Gastroenterol Hepatol. 2014. PMID: 24987822 Clinical Trial.
Anti-HDV IgM as a marker of disease activity in hepatitis delta.
Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, Yalcin K, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Bremer B, Stift J, Grabowski J, Kirschner J, Port K, Cornberg M, Falk CS, Dienes HP, Hardtke S, Manns MP, Yurdaydin C, Wedemeyer H; HIDIT-2 Study Group. Wranke A, et al. Among authors: port k. PLoS One. 2014 Jul 29;9(7):e101002. doi: 10.1371/journal.pone.0101002. eCollection 2014. PLoS One. 2014. PMID: 25072849 Free PMC article.
55 results